30 results about "Immune Cell Function" patented technology

This disclosure describes an artificial expression construct containing a PD1:cytokine chimeric transgene under the control of an inducible promoter. The artificial expression construct of this disclosure can be used to enhance the function of immune cells (e.g., CAR-T cells) that have recombinant receptors. The inducible PD1:cytokine chimeric transgene disclosed herein enhances the potency of immune cells (e.g., CAR-T cells) that have recombinant receptors, thereby enhancing killing, proliferation of immune cells, and / or cytokine production.

The invention provides an immune senescence detection marker Granzyme B, an immune senescence regulation and control target BHLHE40 and application, and belongs to the technical field of biological medicine. The invention discloses the continuous up-regulation characteristic of the GZMB in the senescence process of the primate immune system for the first time, defines the consistent expression trend of the GZMB in various immune tissues, and determines that the GZMB can be used as a reliable molecular marker for reflecting the overall immune senescence state. The invention also discloses a key regulatory pathway for immune aging, and finds that the GZMB can activate an NF-kappa B signal pathway, up-regulate inflammation and aging related genes such as CDKN1A, NFKBIA and S100A4, and promote functional degradation of immune cells; it is identified that the transcription factor BHLHE40 is a key upstream regulation factor of GZMB, expression of GZMB and downstream senescence genes can be remarkably reduced by knocking down BHLHE40, and the core effect of the BHLHE40-GZMB pathway in immune senescence is clarified.

The invention belongs to the technical field of biological medicines, and particularly discloses application of aspirin in enhancing the curative effect of tumor infiltrating lymphocyte on treating liver cancer. The invention discloses application of aspirin in preparation of a medicine for enhancing the curative effect of tumor infiltrating lymphocyte on hepatocellular carcinoma. The invention discloses an application of aspirin in enhancing the curative effect of tumor infiltrating lymphocyte on treating liver cancer, the aspirin overcomes the problem of drug resistance of TIL therapy in HCC by adjusting the immune cell function in a tumor microenvironment, and the treatment effect is improved.

The invention discloses a broncholung lavage fluid composition for treating non-small cell lung cancer, and relates to the technical field of cancer treatment. The preparation method of the bronchus lung lavage fluid composition for treating the non-small cell lung cancer comprises the following steps: S1, performing metagenome sequencing on a BALF sample, S2, grouping by R / NR based on differential strains obtained in S1 to obtain core bacteria, performing single-strain Kaplan-Meier survival analysis on the strains, and determining the survival rate of the single-strain Kaplan-Meier to obtain the bronchus lung lavage fluid composition for treating the non-small cell lung cancer. Finally, seven key microorganisms, namely bronchopulmonary lavage fluid combinations, which are remarkably related to immunotherapy PFS are locked; s3, determining the relationship between the seven key BALF bacteria and the existing immune therapeutic effect marker; and S4, verifying the generation conditions of IL6, IL8 and RANTES cytokines promoted by the seven strains through an in-vitro cell experiment, and revealing the activation and enhancement effects of the seven strains on immune cell functions. According to the invention, the immunotherapy effect of the non-small cell lung cancer patient can be promoted to be improved by combining a plurality of beneficial specific microorganisms in an airway administration mode. In conclusion, the method has a good application prospect.

The present application relates to the technical field of biological medicine, and particularly relates to application of fullerenol in preparation of tumor prevention or treatment drugs for inducing trained immunity. The present application finds that fullerenol can induce formation of trained immunity, activate immune reprogramming of bone marrow hematopoietic stem cells, produce long-term pro-inflammatory phenotype, form persistent immune memory, and further enhance functions of innate immune cells. It is verified by experiments that fullerenol can significantly inhibit tumor growth in an animal model without obvious systemic toxicity; epigenetic remodeling of bone marrow hematopoietic stem cells can be sustained for several weeks to several months, and has long-acting anti-recurrence potential. In addition, trained immunity induced by fullerenol can be used for immune regulation of various solid tumors, and fullerenol is simple in synthesis, can be produced on a large scale, has excellent biocompatibility and stability. Therefore, the present application has wide application prospect.

The invention provides an oral liquid based on algal oil-curcumin synergistic anti-inflammation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The oral liquid comprises the following raw materials: an anti-inflammatory agent (consisting of algae oil and curcumin), a traditional Chinese medicine extract (consisting of a herba houttuyniae extract and an Indian kalimeris herb extract), phospholipid, fructo-oligosaccharide, an antioxidant, a stabilizer (consisting of Arabic gum and hydroxypropyl-beta-cyclodextrin) and a flavoring agent. Experimental results show that the anti-inflammatory oral liquid is high in stability, and the content of inflammatory factors in mice with LPS-induced chronic inflammation can be remarkably reduced. The oral liquid can relieve chronic inflammation symptoms by regulating immune cell functions, blocking inflammation signal channels and other multi-target mechanisms, is high in safety after being used for a long time, does not have obvious adverse reaction, and provides a new choice for clinical treatment of chronic inflammatory diseases.

The invention relates to a piezoelectric nano-material with ultrasonic responsiveness, which is a PVP (Polyvinyl Pyrrolidone) modified bismuth oxyiodate nano-sheet, the particle size is 100-200 nm, and a surface electric field can be generated under the ultrasonic action. The piezoelectric nano material can hyperpolarize the potential of a T cell membrane and inhibit an ion channel Kv1.3 regulated and controlled by the membrane potential, so that Th17 cell differentiation is reduced, and joint inflammation is relieved; the piezoelectric nano material is further prepared into a joint injection preparation, and the joint injection preparation can be combined with ultrasonic irradiation to be applied to treatment of rheumatoid arthritis. According to the invention, the piezoelectric nano material is successfully applied to immune microenvironment regulation and control of rheumatoid arthritis for the first time, and the product and technology blank in the field of'precisely regulating and controlling immune cell functions by using physical signals to treat autoimmune diseases' is filled.

The methods and compositions disclosed herein relate to the field of cell therapy, and more specifically, to improving CAR and / or TCR function through improvement of the tumor microenvironment via improvement in cytokine signaling. Methods of treating a cancer in a patient are disclosed comprising administering to the patient immune cells expressing a chimeric antigen receptor or T-cell receptor and a membrane bound IL-18. Further disclosed are nucleic acids which encode a membrane bound IL-18 and methods for culturing cells expressing such nucleic acids.

The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and methods for using the modified immune effector cell for treatment of diseases (e g., adoptive cell therapy).

The invention relates to an application of a CXCL13 + CD8 + T cell subset in preparation of a product for predicting prognosis of a melanoma patient, and the CXCL13 + CD8 + T cell subset is used as an analysis target to prepare a reagent for analyzing immune cell functions. Wherein the CXCL13 < + > CD8 < + > T cell subset refers to a CD8 < + > T cell subset capable of releasing a CXCL13 signal. Compared with the prior art, the research shows that by analyzing the expression level of effector molecules and immune checkpoint molecules in a tumor microenvironment and the density of a three-level lymph structure, the prognosis of a tumor patient can be more accurately predicted, and the reactivity of tumors to immunotherapy can be predicted; at present, a report for reflecting immune characteristics of melanoma by using the CXCL13 + CD8 + T cell subset as a biomarker is not found. The infiltration level of CXCL13 + CD8 + T cells in tumor tissues is quantitatively evaluated through flow cytometry, and more accurate and sensitive indexes are provided for prognosis evaluation of melanoma and liver cancer patients.

The present disclosure provides polypeptide constructs that, when exposed to sufficient levels of ATP, cause them to assemble into dimers or higher order complexes (e.g., trimers, tetramers, etc.), thereby acting as immune cell function agonists. The constructs can also be conjugated to one or more therapeutic, chemotherapeutic, or labeling agents. The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cells and / or NK cells) that function to promote an anti-tumor immune response, and delivering the conjugated agent to the tumor microenvironment. The constructs can be used as anti-cancer / therapeutic agents for the treatment of solid tumors with elevated ATP levels.

This invention provides a method for generating immune cells with enhanced function. [Solution] A method for enhancing the function of immune cells is disclosed herein, comprising modifying immune cells to inhibit the function of at least one gene selected from the group consisting of RC3H1, RC3H2, A2AR, FAS, TGFBR1, and TGFBR2. A method also disclosed herein, comprising modifying stem cells or progenitor cells that can differentiate into immune cells to inhibit the function of at least one gene selected from the group consisting of RC3H1, RC3H2, A2AR, FAS, TGFBR1, and TGFBR2. The use of immune cells or stem cells produced by this method, and immune cells in therapeutic treatments, is also disclosed herein.

The present disclosure relates to methods of coupling antic-cancer agents and anti-cancer treatments to improve the efficacy of the overall treatment. The anti-cancer agent reduces stroma in the tumor microenvironment, in part by killing stroma producing cells such as TAFs and TAMs. Reduction of tumor stroma not only improves immune cell function, including immune cells administered in a second treatment, but also allows allowing other anti-cancer treatments to better access to tumor cells.

The invention relates to the field of neurology, neurobiology, and neurological disorders. The invention relates to a pharmaceutical combination comprising a colony-stimulating factor 1 receptor (CSFR1R) inhibitor and a bone marrow cell population for use in the treatment of central nervous system (CNS) diseases. The invention further relates to an ex vivo method for depleting dysfunctional and / or mutant microglia and / or CNS-associated macrophages (CAM), the method comprising providing a population of cells comprising myeloid cells and treating said cells with an CSF1R inhibitor of central nervous system (CNS)-associated myeloid cells, thereby depleting dysfunctional and / or mutant microglia. The invention relates to a cell population according to the ex vivo method. The invention further relates to a pharmaceutical composition comprising the CSF1R inhibitor according to the present invention for use in the treatment or prevention of a medical condition induced by dysfunction of immune cells in a central nervous system (CNS), additionally comprising a pharmaceutically acceptable carrier.

The invention relates to the technical field of edible mushroom polysaccharide extraction, in particular to agrocybe cylindracea beta-1, 3-glucan as well as a preparation method and application thereof. The preparation method comprises the following steps: adding agrocybe cylindracea sporocarp and water, extracting at 80-90 DEG C for 2-3 hours, and extracting for 2-3 times; after extraction, combining the two filtrates to obtain an extracting solution I; drying the residues, adding the dried residues into an alkaline solution, extracting for 2-3 times at 70-90 DEG C, combining the two extracting solutions, and adjusting the pH value to be neutral to obtain an extracting solution II; combining the extracting solution I and the extracting solution II to obtain a total extracting solution; carrying out micro-filtration membrane treatment on the total extracting solution, collecting a non-permeated solution, freeze-drying, re-dissolving in water, adding an ethanol solution with the concentration of 90-95%, and carrying out alcohol precipitation treatment; and collecting the precipitate, and freeze-drying to obtain the agrocybe cylindracea beta-1, 3-glucan. The agrocybe cylindracea beta-1, 3-glucan has the advantages that the agrocybe cylindracea beta-1, 3-glucan can be used for improving the innate immune cell function by training immunity and enhancing the body immunity.

The invention relates to a multiple shRNA combination and application thereof, and belongs to the technical field of biology. The combination comprises a first transcription unit, a second transcription unit and a third transcription unit which are located on the same expression vector and respectively silence three different target genes in a targeted manner. Each transcription unit comprises an RNA (Ribonucleic Acid) polymerase III promoter, an shRNA (Short Hairpin Ribonucleic Acid) coding sequence and a transcription termination signal; and promoters for driving the three transcription units are different from one another and are selected from any three of hU6, mU6, hH1, h7SK, mini-hU6, H1-7SK and hH1-core. According to the technology, simultaneous efficient, stable and lasting silencing of three target genes is realized by avoiding homologous recombination, nucleic acid constructs and expression vectors can be constructed and introduced into immune cells, the functions of the immune cells are effectively enhanced, and the method has application prospects in the fields of treatment of tumors, autoimmune diseases, senescence-related diseases and the like.

The invention provides an anti-human CD226 antibody and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the CDR1, the CDR2 and the CDR3 of the heavy chain variable region are amino acid sequences as shown in SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3 respectively; the CDR1, the CDR2 and the CDR3 of the light chain variable region are amino acid sequences as shown in SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6 respectively. The anti-human CD226 antibody disclosed by the invention is detected by using a flow cytometer, and the expression condition of CD226 on cells is judged according to the intensity change of a CD226 fluorescence signal, so that the functional state of human immune cells is judged in an auxiliary manner.

The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and methods for using the modified immune effector cell for treatment of diseases (e.g., adoptive cell therapy).

The present disclosure is directed to systems for inhibiting NFAT and / or NFkB signaling to improve the function of CAR expressing immune cells, e.g., CAR T cells. The system enables generation of immune cells engineered to express a CAR or multiple combinations of CARs (multi-CAR) and inhibitors of NFAT and / or NFkB signaling.

Disclosed are methods for enhancing the memory-like state of immune cells by treating the cells with itaconate. Enhancing the memory-like state improves immune cell function and persistence. Also disclosed are methods of using the enhanced immune cells for treating cancer and autoimmune diseases.

The invention discloses a wolfberry-astragalus compound polysaccharide with an immunity enhancing effect as well as a preparation method and application thereof, and belongs to the technical field of natural active polysaccharides and immunoregulation. The wolfberry-astragalus compound polysaccharide is obtained by separately extracting and purifying wolfberry polysaccharide and astragalus polysaccharide and compounding according to a specific mass ratio, and the total sugar content is 70-80%, the uronic acid content is 10-14%, and the protein content is 15-25%. In-vitro cell experiments and in-vivo animal experiments verify that the wolfberry-astragalus compound polysaccharide can significantly promote the phagocytic function of macrophages, up-regulate the secretion of NO, TNF-alpha and IL-6, significantly promote the functions of immune cells, and improve the indexes of immune organs and the level of immune globulin, thereby enhancing the immune function of the organism. The compound is stable in preparation process, high in purity, natural in source and high in safety, can be used for preparing medicines, health foods or functional foods for enhancing immunity or improving immunocompromise, and has a good application prospect.

[0003] Artificial expression constructs are described that include a cytokine transgene under the control of an inducible promoter. The artificial expression constructs of the present disclosure can be used to enhance the function of immune cells (e.g., CAR-T cells) bearing the recombinant receptor. The cytokine transgenes disclosed herein enhance the efficacy of immune cells (e.g., CAR-T cells) bearing the recombinant receptor, enhancing killing, immune cell proliferation, and / or cytokine production.

The invention provides a pharmaceutical composition and application thereof, and belongs to the technical field of biological medicine. The sphingolipid metabolite is added in the immune cell in-vitro culture process, the immune cell function is remodeled in a metabolic regulation mode, and the dryness and tumor killing capacity of the immune cells are remarkably enhanced.

The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and / or TCR function through improvement of improvement of cytokine signaling.

This invention provides an injectable pH-responsive hydrogel nanoparticle, its preparation method, and its applications, relating to the field of bionanomedicine technology. First, nintedanib, zinc ions, and D780 are self-assembled to prepare nanoparticles (NPs). Then, the nanoparticles are cross-linked with an OP hydrogel to obtain injectable pH-responsive hydrogel nanoparticles (OP@NPs). These OP@NPs not only possess a stable structure and injectability but also achieve efficient drug delivery through a pH-triggered release mechanism. Furthermore, OP@NPs can significantly enhance anti-tumor immune responses and effectively inhibit tumor growth by activating in vivo immune cells, improving lactate metabolism, and enhancing immune cell function. They exhibit potent anti-tumor effects and inhibition of osteosarcoma lung metastasis both in vivo and in vitro. When used in combination with the PD-1 antagonist pembrolizumab, they demonstrate great potential as a sensitizer for anti-tumor immunotherapy. This invention provides innovative strategies and new insights for osteosarcoma immunotherapy.

The present disclosure provides cells and hematopoietic organoid compositions, and methods of making and using the same for bone marrow transplants, cell therapy and treatment of diseases or disorders associated with hematopoietic cell disfunction or deficiency and / or immune cell disfunction or deficiency.

The invention relates to a biological age prediction method and system, and belongs to the technical field of biological prediction.The method comprises the steps that a peripheral blood sample of a crowd is collected; obtaining immune cell function indexes from a peripheral blood sample based on flow cytometry, and detecting blood biochemical indexes at the same time; screening out key indexes with high contribution degree to biological age prediction from immune cell function indexes and blood biochemical indexes based on a statistical method and a feature selection algorithm; and inputting the key indexes into a machine learning model trained based on the key indexes to obtain a biological age prediction result. According to the method, high-precision prediction of the biological age is realized through multi-dimensional data.

The present disclosure provides polypeptide constructs that act as agonists of immune cell function when exposed to sufficient levels of ATP to cause their assembly into dimers or higher level complexes (e.g., trimers, tetramers, etc.). The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cell and / or NK cells) that function to promote anti-tumor immune responses. The constructs may be employed as anticancer agents / therapeutics for the treatment of solid tumors that have elevated levels of ATP.

The present invention aims to provide a method for preventing and treating myopia and a composition for use therein. [Solution] The present invention provides a method and composition for suppressing, improving, or treating myopia by administering choroidal resident immune cell function modifiers such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediator release inhibitors, or lactic acid bacteria. Inducing polarization of M2 macrophages in the choroid, or regulating the function of choroidal resident immune cells by administering mast cell stabilizers, chemical mediator release inhibitors, or lactic acid bacteria, is effective in preventing and treating myopia.

The present disclosure provides methods and artificial expression constructs for improving the persistence or function of immune cells. In particular, the methods or artificial expression constructs include a mutant interleukin 15 (IL-15) transgene controlled by a constitutive or inducible promoter to enhance the function of immune cells. The mutant IL-15 is modified to concentrate signaling in a cell expressing IL-15R [alpha] and / or a signaling complex comprising IL-15R [alpha]. More specifically, the present disclosure provides methods and artificial expression constructs for enhancing immune cell function by enhancing immune cell proliferation, reducing antigen independent gamma interferon (IFN gamma) release, and inhibiting tumor growth and uncontrolled immune cell proliferation.